{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T00:17:20Z","timestamp":1793146640250,"version":"4.5.0"},"reference-count":0,"publisher":"Bentham Science Publishers Ltd.","issue":"3","funder":[{"DOI":"10.13039\/501100001411","name":"Indian Council of Medical Research","doi-asserted-by":"publisher","award":["(ISRM\/11(94)\/2019)"],"award-info":[{"award-number":["(ISRM\/11(94)\/2019)"]}],"id":[{"id":"10.13039\/501100001411","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["eurekaselect.com"],"crossmark-restriction":true},"short-container-title":["CDS"],"published-print":{"date-parts":[[2021,11,30]]},"abstract":"<jats:sec>\n<jats:title>Background:<\/jats:title>\n<jats:p>Gallstone disease (GSD) is one of the most common gastroenterological\ndisorders. It is known that drospirenone causes small increased risk of gallbladder diseases. However,\nthe risk may vary between different adverse drug reaction databases.<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>Objective:<\/jats:title>\n<jats:p>The purpose of this studty is to examine the safety and risk association between hormonal\ncontraceptive drospirenone and gallbladder diseases using adverse drug reaction database of\nUSFDA\u2019s Federal Adverse Events Reporting System (FAERS), Europe\u2019s Eudravigilance (EV) and\nCanada\u2019s Canada Vigilance Adverse Reaction Online Database (CVARD).<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>Methods:<\/jats:title>\n<jats:p> Individual Case Safety Reports of patients till October 2019 were downloaded from the\nFederal Adverse Event Reporting System, Eudravigilance, and Canadian database. These reports\ncontained information on adverse events associated with all other drugs inclusive of drospirenone.\nThe disproportionality method of data mining was used to calculate the risk association.<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>Results:<\/jats:title>\n<jats:p>The lower limit of 95% CI of PRR was 3.27, 3.47 and 3.76, PRR was 33.08, 41.35 and\n115.42, ROR was 37.20, 44.61 and 127.19, Chi-square value was 126572.89, 110392.95 and\n362.46, and IC-2SD value was 0.16, 0.17, and 1.21 for FAERS, EU, and CVARD respectively indicating\na week signal. Also, all the calculated parameters were above the threshold value.<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>Conclusion:<\/jats:title>\n<jats:p> From our study, it was clear that the risk between drospirenone and gallbladder diseases\nwas very low among three databases. There was no harm in prescribing this drug for a contraceptive\naction.<\/jats:p>\n<\/jats:sec>","DOI":"10.2174\/1574886315999201027150243","type":"journal-article","created":{"date-parts":[[2020,10,28]],"date-time":"2020-10-28T06:19:32Z","timestamp":1603865972000},"page":"272-277","update-policy":"https:\/\/doi.org\/10.2174\/bsp_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Comparative Safety Assessment Study for Drospirenone Induced Gallbladder Diseases Using the Adverse Drug Reaction Database of USA, Europe, and Canada"],"prefix":"10.2174","volume":"16","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2515-0307","authenticated-orcid":true,"given":"Manan","family":"Shah","sequence":"first","affiliation":[{"name":"Department of Pharmaceutical Analysis, Institute of Pharmacy, Nirma University, Ahmedabad, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5072-1330","authenticated-orcid":true,"given":"Charmy","family":"Kothari","sequence":"additional","affiliation":[{"name":"Department of Pharmaceutical Analysis, Institute of Pharmacy, Nirma University, Ahmedabad, India"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"965","container-title":["Current Drug Safety"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/eurekaselect.com\/article\/download\/187253","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.eurekaselect.com\/187253\/article","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/eurekaselect.com\/article\/download\/187253","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,12,15]],"date-time":"2021-12-15T09:50:41Z","timestamp":1639561841000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.eurekaselect.com\/187253\/article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,11,30]]},"references-count":0,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2021,11,30]]}},"alternative-id":["LiveAll1"],"URL":"https:\/\/doi.org\/10.2174\/1574886315999201027150243","relation":{},"ISSN":["1574-8863"],"issn-type":[{"value":"1574-8863","type":"print"}],"subject":[],"published":{"date-parts":[[2021,11,30]]},"assertion":[{"value":"Peer Reviewed","order":0,"name":"review_status","label":"Review Status","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Single blind","order":1,"name":"review_process","label":"Review Process","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Checked with iThenticate","order":0,"name":"screening_status","label":"Screening Status","group":{"name":"plagiarism_screening","label":"Plagiarism Screening"}},{"value":"2020-05-13","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-09-03","order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-09-30","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-11-30","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}